Publication:
Efficacy of injectable platelet-rich fibrin in the erosive oral lichen planus: a split-mouth, randomized, controlled clinical trial

Simple item page
dc.contributor.authorSaglam, Ebru
dc.contributor.authorOzsagir, Zeliha Betul
dc.contributor.authorUnver, Tugba
dc.contributor.authorAlinca, Suzan Bayer
dc.contributor.authorToprak, Ali
dc.contributor.authorTunali, Mustafa
dc.contributor.institutionauthorÜNVER, TUĞBA
dc.contributor.institutionauthorTOPRAK, ALİ
dc.date.accessioned2021-10-26T20:59:13Z
dc.date.available2021-10-26T20:59:13Z
dc.date.issued2021-01-01T00:00:00Z
dc.description.abstractObjective: Our study compared the effects of injectable platelet-rich fibrin (i-PRF) with those of corticosteroids in the treatment of erosive oral lichen planus (EOLP). Methodology: This split-mouth study included 24 individuals diagnosed histopathologically with bilateral EOLP. One bilateral lesion was injected with i-PRF, whereas the other was injected with methylprednisolone acetate in four sessions at 15-day intervals. Visual analog scale (VAS) for pain and satisfaction, oral health impact profile scale-14, and the lesion size were used. Results: The intragroup comparisons showed a significant decrease in VAS-pain and lesion size in both the i-PRF group (from 81.88 +/- 17.74 to 13.33 +/- 18.34, and from 4.79 +/- 0.41 to 1.88 +/- 1.08, respectively) and the corticosteroid group (from 80.21 +/- 17.35 to 23.33 +/- 26.81, and from 4.71 +/- 0.46 to 2.21 +/- 1.35, respectively) in the 6th month compared to baseline (p<0.001). Moreover, VAS-satisfaction increased significantly in both the i-PRF group (from 26.67 +/- 17.8 to 85.63 +/- 16.24) and the corticosteroid group (from 28.33 +/- 17.05 to 74.38 +/- 24.11) in the 6th month compared to baseline (p<0.001). However, no significant difference in any value occurred in the intergroup comparisons. Conclusion: In patients with EOLP, both methods decreased pain and lesion size similarly, and both increased satisfaction. Therefore, the use of i-PRF may be considered an option in cases refractory to topical corticosteroid therapy. Biochemical and histopathological studies are required to reveal the mechanism of i-PRF action in EOLP treatment.
dc.identifier.doi10.1590/1678-7757-2021-0180
dc.identifier.pubmed34614123
dc.identifier.scopus85117087878
dc.identifier.urihttp://hdl.handle.net/20.500.12645/29591
dc.identifier.wosWOS:000706102900001
dc.rightsinfo:eu-repo/semantics/openAccess
dc.subjectCorticosteroid
dc.subjectOral lichen planus
dc.subjectPlatelet-rich fibrin
dc.subjectPatient reported outcome measures
dc.subjectWound healing
dc.titleEfficacy of injectable platelet-rich fibrin in the erosive oral lichen planus: a split-mouth, randomized, controlled clinical trial
dc.typeArticle
dspace.entity.typePublication
local.avesis.id45d38e75-57e0-4881-a805-12d314915afd
local.publication.isinternational1
relation.isAuthorOfPublicationce43fcd9-f865-423e-9c6b-e58a21e8ee1a
relation.isAuthorOfPublicationdbd19639-3d50-40a5-9a13-eb615691f6e4
relation.isAuthorOfPublication.latestForDiscoveryce43fcd9-f865-423e-9c6b-e58a21e8ee1a
Files
Original bundle
Now showing 1 - 1 of 1
Thumbnail Image
Name:
Efficacy of injectable platelet-rich fibrin in the erosive oral lichen planus a split-mouth, randomized, controlled clinical trial.pdf
Size:
3.1 MB
Format:
Adobe Portable Document Format
Description:
Download
Collections
Yayınlar - Eserler